sodium salicylate has been researched along with camptothecin in 1 studies
| Studies (sodium salicylate) | Trials (sodium salicylate) | Recent Studies (post-2010) (sodium salicylate) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
|---|---|---|---|---|---|
| 2,031 | 50 | 171 | 13,002 | 2,229 | 5,391 |
| Protein | Taxonomy | sodium salicylate (IC50) | camptothecin (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
| Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, JR; Huang, TH; Li, TK; Shen, TL; Wen, CY | 1 |
1 other study(ies) available for sodium salicylate and camptothecin
| Article | Year |
|---|---|
Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle Proteins; Cell Death; Cyclooxygenase 2 Inhibitors; DNA Damage; DNA Topoisomerases; DNA-Activated Protein Kinase; DNA-Binding Proteins; Drug Interactions; HCT116 Cells; Humans; NF-kappa B; Phosphorylation; Protein Serine-Threonine Kinases; Replication Protein A; Signal Transduction; Sodium Salicylate; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |